VVOS — Vivos Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $18.61m
- $24.42m
- $15.03m
Annual income statement for Vivos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 13.1 | 16.9 | 16 | 13.8 | 15 |
| Cost of Revenue | |||||
| Gross Profit | 10.4 | 12.6 | 10 | 8.27 | 9.02 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 25.1 | 37.3 | 39.8 | 31.1 | 26.2 |
| Operating Profit | -12 | -20.4 | -23.7 | -17.3 | -11.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12.1 | -20.3 | -23.8 | -13.6 | -11.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -12.1 | -20.3 | -23.8 | -13.6 | -11.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12.1 | -20.3 | -23.8 | -13.6 | -11.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -12.1 | -20.3 | -23.8 | -13.6 | -11.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -16.6 | -22.8 | -27.3 | -11.1 | -2.22 |
| Dividends per Share |